Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

Suggested remit: To appraise the clinical and cost effectiveness of nivolumab in combination with ipilimumab, within its marketing authorisation, for untreated non-small-cell lung cancer in adults who have a high tumour mutational burden.

Following on from information provided to NICE by the company in May 2019, the appraisal of Lung cancer (non-small-cell, untreated, high tumour mutational burden) - ipilimumab (with nivolumab) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

Status:

Discontinued

Technology type:

Medicine

Decision:

Prioritised

Process:

TA

ID number:

1187

Email enquiries

If you have any queries please email scheduling@nice.org.uk

External Assessment Group:

Kleijnen Systematic Reviews

Stakeholders

Companies sponsors

Bristol-Myers Squibb (nivolumab, ipilimumab)

Others

Department of Health and Social Care

 

NHS England

 

Welsh Government

Patient carer groups

Roy Castle Lung Cancer Foundation

Professional groups

Association of Cancer Physicians

 

British Thoracic Oncology Group

 

Cancer Research UK

 

Royal College of Physicians

 

Royal College of Radiologists

Comparator companies

Accord Healthcare (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) (Confidentiality agreement not signed, not participating)

 

Allergan (docetaxel, gemcitabine, paclitaxel, pemetrexed, vinorelbine) (Confidentiality agreement not signed, not participating)

 

Celgene (paclitaxel) (Confidentiality agreement not signed, not participating)

 

Dr Reddy’s laboratories (docetaxel) (Confidentiality agreement not signed, not participating)

 

Eli Lilly (gemcitabine, pemetrexed) (Confidentiality agreement not signed, not participating)

 

Hospira UK (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel) (Confidentiality agreement not signed, not participating)

 

Medac GmbH (docetaxel, gemcitabine, paclitaxel, vinorelbine) (Confidentiality agreement not signed, not participating)

 

Merck Sharp and Dohme (pembrolizumab)

 

Pfizer (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) (Confidentiality agreement not signed, not participating)

 

Pierre Fabre (vinorelbine) (Confidentiality agreement not signed, not participating)

 

Sandoz (cisplatin) (Confidentiality agreement not signed, not participating)

 

Sanofi (docetaxel) (Confidentiality agreement not signed, not participating)

 

Seacross pharmaceuticals (docetaxel, paclitaxel, pemetrexed) (Confidentiality agreement not signed, not participating)

 

Sun Pharmaceuticals (carboplatin, gemcitabine) (Confidentiality agreement not signed, not participating)

 

Teva UK (docetaxel) (Confidentiality agreement not signed, not participating)

General commentators

All Wales Therapeutic and Toxicology Centre

 

British National Formulary

 

Department of Health, Social Services and Public Safety for Northern Ireland

 

Healthcare Improvement Scotland

 

Welsh Health Specialised Services Committee

Relevant research groups

Genomics England

 

Institute of Cancer Research

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual